Table 2.
Chosen clinical trials investigating antibodies targeting immune checkpoints in therapies of patients with solid tumours including NSCLC.
| Trial ID | Target | Treatment Method | Line of Treatment | Cancer Type | Primary End Points | Phase |
|---|---|---|---|---|---|---|
| NCT02964013 | TIGIT PD-1 |
vibostolimab + pembrolizumab |
1st or 2nd |
solid tumours (including NSCLC) |
DLTs | 1 |
| NCT04738487 | TIGIT PD-1 |
vibostolimab + pembrolizumab versus pembrolizumab |
1st | PD-L1+ metastatic NSCLC |
OS, PFS | 3 |
| NCT04725188 | TIGIT PD-1 |
vibostolimab + pembrolizumab or vibostolimab + pembrolizumab + docetaxel versus docetaxel |
2nd | metastatic NSCLC | PFS | 2 |
| NCT03563716 | TIGIT PD-L1 |
tiragolumab + atezolizumab versus placebo + atezolizumab |
1st | advanced PD-L1-selected NSCLC | ORR, PFS | 2 |
| NCT02608268 | TIM-3, PD-1 | sabatolimab (MBG453) alone or sabatolimab + spartalizumab (PDR001) |
1st or subsequent |
advanced solid tumours (including NSCLC) |
DLTs, ORR and others | 1/2 |
| NCT02817633 | TIM-3, LAG-3, PD-1 | TSR-022 (anti-TIM-3), TSR-033 (anti-LAG-3), TSR-042 (anti-PD-1), nivolumab and chemotherapy in different combinations |
1st, 2nd or 3rd | advanced solid tumours (including NSCLC) |
DLTs, ORR and others | 1 |
| NCT02460224 | LAG-3, PD-1 | ieramilimab (LAG525) + spartalizumab (PDR001) |
1st or subsequent |
advanced solid tumours (including NSCLC) |
DLTs, ORR | 1/2 |
| NCT01644968 | OX40 | 9B12 | failure of all standard therapeutic options | metastatic solid malignancies |
DLTs | 1 |
| NCT02410512 | OX40, PD-L1 |
MOXR0916 + atezolizumab |
failure of all standard therapeutic options | advanced solid tumours (including NSCLC) |
DLTs | 1 |
| NCT00309023 NCT00612664 NCT01471210 (integrated) | CD137 | urelumab | 2nd or subsequent | advanced solid tumours and lymphoma | AEs, DLTs | 1 or 2 |
| NCT02179918 | CD137, PD-1 |
utomilumab (PF-05082566) + pembrolizumab |
failure of all standard therapeutic options | advanced or metastatic solid tumours | AEs, DLTs | 1 |
| NCT01307267 | CD137 | utomilumab | 1st or subsequent |
advanced malignancies (including NSCLC) |
DLTs | 1 |
| NCT03088540 | PD-1 | cemiplimab versus chemotherapy |
1st | NSCLC | OS, PFS | 3 |
| NCT02404441 | PD-1 | spartalizumab | averagely 4th | solid tumours (including NSCLC) | DLTs, ORR | 1/2 |
| NCT03629925 | PD-1 | sintilimab + platinum compounds + gemcitabine (GP) versus placebo + GP |
1st | squamous NSCLC | PFS | 3 |
| NCT02517398 | TGF-β PD-L1 |
bintrafusp alfa (bispecific) |
2nd | solid tumours (including NSCLC) | TEAEs, DLTs, BOR |
1 |
| NCT03631706 | TGF-β PD-L1 |
bintrafusp alfa (bispecific) versus pembrolizumab |
1st | metastatic NSCLC with high PD-L1 expression |
PFS, OS | 3 |
| NCT03761017 | PD-1 CTLA-4 |
MGD019 (bispecific) |
averagely 4th | solid tumours (including squamous NSCLC) |
TEAEs | 1 |
| NCT03530397 | PD-1 CTLA-4 |
MEDI5752 (bispecific) |
1st or subsequent |
advanced solid tumours (including NSCLC) |
TEAEs, DLTs and others |
1 |
AEs—adverse events, BOR—best overall response, DLTs—dose limiting toxicities, ORR—overall response rate, OS—overall survival, PFS—progression-free survival, TEAEs—treatment emergent adverse events.